Overview

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Status:
Completed

Trial end date:
2021-03-17

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BeiGene USA, Inc.

Treatments:

Dacarbazine
Molecular Mechanisms of Pharmacological Action
Poly(ADP-ribose) Polymerase Inhibitors
Temozolomide